Fig. 1From: Management of asthma patients during the COVID-19 pandemic: pathophysiological considerations to address the challengesThe pathophysiology of SARS-CoV-2 and allergic asthma. SARS-CoV-2 binds to the ACE2 receptor and injects its RNA inside the host cell. The dsRNA triggers TLR3 and TLR4 leading to ISG activation and recruitment of immune cells. In severe conditions, the immune cells lead to cytokine storms which can trigger asthma symptoms. On the other hand, allergens can form complexes with high-affinity IgE and low-affinity IgE, which can trigger immune cells to release cytokines and other mediators that lead to the formation of mucus plugs, bronchoconstriction, airway remodeling, and other asthma symptoms. In SARS-CoV-2 patients with asthma, the recruitment of immune cells and the release of cytokines from both pathways can lead to severe organ damage and other harmful effects. This picture was created with BioRender and downloaded with a premium subscriptionBack to article page